All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
Rituximab and high-dose cytarabine (HD-Ara-C) induction immunotherapy, followed by autologous stem cell transplantation (auto-SCT), has significantly improved the prognosis of patients with mantle cell lymphoma (MCL).1 Results from the HOVON 45 trial reported 4‐year progression‐free survival (PFS) rate of 44% and 4‐year overall survival (OS) rate of 66% for the three cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) followed, in responding patients, by one cycle of HD‐Ara‐C and autoSCT.2 However, most patients with MCL relapse after auto-SCT. Bortezomib is a protease inhibitor approved for the treatment of relapsed/refractory MCL.3
Here, we present the results of HOVON 75 - a randomized phase II study, recently published in British Journal of Haematology. Jeanette Doorduijn and colleagues investigated the outcome of a modified chemo-immuno regimen and auto-SCT with or without maintenance therapy with bortezomib for treatment of patients with MCL.
Table 1. Patients characteristics
WHO, World Health Organization |
|||
All patients n = 135 |
Randomized patients after auto-SCT |
||
---|---|---|---|
No further treatment, n = 30 |
Bortezomib maintenance, n = 30 |
||
Age (median, range) |
57 (34–66) |
54 (36–65) |
56 (34–66) |
Male sex |
78% |
77% |
80% |
WHO performance |
|||
WHO 0 |
105 (78%) |
25 (83%) |
25 (83%) |
WHO 1 |
60 (19%) |
5 (17%) |
4 (13%) |
WHO 2 |
5 (4%) |
– |
1 (3%) |
Ann Arbor stage |
|||
II |
11 (8%) |
1 (3%) |
3 (10%) |
III |
8 (6%) |
2 (7%) |
2 (7%) |
IV |
116 (86%) |
27 (90%) |
25 (83%) |
This HOVON 75 trial was designed to improve the outcomes achieved in the earlier HOVON 45 trial,2 and to investigate if bortezomib maintenance after auto-SCT could improve outcomes.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox